Additionally, these genes exhibited subtype-specific immune interactions and drug response profiles, with PPARG emerging as a particularly strong therapeutic biomarker.<h4>Conclusion</h4>This study identified and experimentally validated four hub genes as potential biomarkers and therapeutic targets in breast cancer. The gene discussed is PPARG; the disease is breast cancer.